Clinical experience with romiplostim
https://doi.org/10.17650/1818-8346-2014-9-1-42-46
Abstract
Twenty patients with primary immune thrombocytopenia (ITP) received romiplastim as a second line therapy, and 3 patients with secondary thrombocytopenia as off-label. Romiplostim appeared effective in 85 % of patients with both persistent and chronic primary ITP. In patients with resistant and refractory ITP romiplostim response has not been registered, or it was lost. Achieving complete response to romiplostim therapy allowed its cancelation in 30 % of patients while maintaining the therapeutic effect; 15 % of patients switched to the 1 injection/biweekly in doses 4–5 mg/kg. Adverse events were observed in 21 % of patients and were temporary. With long-term use drug efficacy is not reduced, and the frequency of adverse events do not increase. Short course of romiplostim was successfully applied before surgical intervention for correction of thrombocytopenia in 3 patients with rheumatic diseases.
About the Authors
G. B. Kuchma
ГБОУ ВПО «Оренбургская государственная медицинская академия» Минздрава России
Russian Federation
Russian Federation
L. K. Kozlova
ГБОУ ВПО «Оренбургская государственная медицинская академия» Минздрава России
Russian Federation
Russian Federation
Ye. Ye. Kuznetsova
ГБУЗ «Оренбургская областная клиническая больница»
Russian Federation
Russian Federation
S. B. Borisyuk
ГБУЗ «Оренбургская областная клиническая больница»
Russian Federation
Russian Federation
References
1. Цветаева Н.В., Никулина О.Ф., Сорокина О.М. и др. Новые принципы лечения персистирующей и резистентной иммунной тромбоцитопении агонистами тромбопоэтиновых рецепторов. Гематол
2. и трансфузиол 2012;3(приложение): 143–4.
3. Голенков А.К., Горенков Р.В. Лечение первичной иммунной тромбоцитопении. Пособие для врачей. М., 2012. 31 с.
4. Лисуков И.А., Масчан А.А., Шамардина А.В. и др. Иммунная тромбоцитопения: клинические проявления и ответ на терапию. Промежуточный анализ данных Российского регистра пациентов с первичной иммунной тромбоцитопенией и обзор литературы. Онкогематология 2013;2:61–9.
5. Kuter D.J., Bussel J.B., Lyons R.M. et al. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomized controlledtrial. Lancet 2008;371(9610):395–03.
6. Jenssens A., Tarantino M., Bird R. et al. Final results from an international, multicenter, single-arm study evaluating the safety and efficacy of romiplostim in adults with primary immune thrombocytopenia (ITP). Blood 2011;118(21):3279.
7. Bussel J.B., Cheng G., Saleh M.N. et al. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N Engl J Med 2007;357:2237–47.
8. Wasser J., Boccia R., Lyons R.M. Use of rituximab in a study comparing the thrombopoietin mimetic romiplostim with immune thrombocytopenia (ITP). Blood 2011;118(21):3282.
9. Boccia R., Kuter D.J., Rummel M.J. et al. The effects of romiplostim or standard of care on splenectomy and treatment failure of patients who had immune thrombocytopenia for less than or egual to one year. Blood 2010;116(21):3702.
10. Rodeghiero F., Stasi R., Gernsheimer T. et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood 2009;113(11): 2386–93.
11. Масчан А.А., Румянцев А.Г., Ковалева Л.Г. и др. Рекомендации Российского совета экспертов по диагностике и лечению больных первичной иммунной тромбоцитопенией. Онкогематология
12. ;3:36–46.
13. Реброва О.Ю. Статистический анализ медицинских данных. Применение пакета прикладных программ STATISTICA. М.: МедиаСфера, 2002. 312 с.
Review
For citations:
Kuchma G.B., Kozlova L.K., Kuznetsova Ye.Ye., Borisyuk S.B. Clinical experience with romiplostim. Oncohematology. 2014;9(1):42-46. (In Russ.) https://doi.org/10.17650/1818-8346-2014-9-1-42-46
Views:
10588
Email this article 